Yellow Jersey Therapeutics
-
JNJ Earnings Hit Growth, But Patent Losses Threaten Future Sales
Johnson & Johnson (NYSE: JNJ) shares fell about 1 percent in early Wednesday trading as investors digested the company’s latest earnings report. Management highlighted confidence in the business, with CEO Joaquin Duato calling the company’s lineup the strongest it has ever had. The market response suggested lingering doubts. Concerns remain around patent losses, litigation exposure,…
